Primary Care Clinics in Rison, AR Accepting Medicare
3 Primary Care Clinics found. Showing 1 - 3
 Mainline Rison Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 505 Sycamore St., Rison, AR 71665 Phone: 870-325-6255 Fax: 870-663-4112 |
Rison Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 505 Sycamore, Rison, AR 71665 Phone: 870-325-6255 Fax: 870-325-6117 |
Access Medical Clinic Arkansas Llc Clinic/Center - Rural Health Medicare: Medicare Enrolled Practice Location: 217 N Main St, Rison, AR 71665 Phone: 888-264-5034 Fax: 870-895-2164 |
News Archive
Oil Can Henry's customers raise $45,401 to support Susan G. Komen for the Cure
Oil Can Henry's customers rose to the challenge in July and helped the company raise $45,401 to support the Oregon and SW Washington Affiliate of Susan G. Komen for the Cure to help save lives and end breast cancer. Over the week-long fundraising effort, Oil Can Henry's locations in Oregon and Southwest Washington performed oil changes on 15,746 vehicles. In addition, customers had the opportunity to donate directly to Komen at the time of service.
Psychological intervention program teaches breast cancer patients how to cope with the disease
A psychological intervention program designed for breast cancer patients reduces the risk of dying if the cancer recurs, new research shows. The study is the latest in a series at Ohio State University that have shown that an intervention program that teaches patients how to cope with the disease can boost their health, well-being and even their chances of survival.
BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV
Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.
Bristol-Myers Squibb announces positive results from Phase 2 study of ipilimumab in patients with NSCLC
Bristol-Myers Squibb Company today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer.
Metabolic testing of COVID-19 patients through skin imprints
There is, therefore, a great need to understand how the illness can be diagnosed using more convenient and inexpensive methods. A new study posted to the medRxiv preprint server reveals the potential role of skin imprints to test for biomarkers that indicate a diagnosis of COVID-19 in a non-invasive way.
› Verified 4 days ago